THOR Insider Trading Activity and SEC Form 4 Filings
THOR insider trading summary
No open-market insider purchases or sales of Synthorx, Inc. (THOR) have been reported on SEC Form 4 in the past 12 months.
Latest THOR insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Dec 11, 2018 | OrbiMed Capital GP VII LLC | 10% Owner | Buy | $15.0M (1,363,636 @ $11.00) |
| Dec 11, 2018 | RA Capital Healthcare Fund LP | 10% Owner | Buy | $50.0M (4,545,455 @ $11.00) |
| Dec 11, 2018 | Ra Capital Management, LLC | 10% Owner | Buy | $50.0M (4,545,455 @ $11.00) |
| Dec 11, 2018 | Peter A. Thompson | Director | Buy | $15.0M (1,363,636 @ $11.00) |
| Dec 11, 2018 | Peter Kolchinsky | Director | Buy | $50.0M (4,545,455 @ $11.00) |
| Dec 11, 2018 | Jay Lichter | Director | Buy | $6.0M (545,455 @ $11.00) |
| Dec 11, 2018 | Avalon Ventures X, L.P. | 10% Owner | Buy | $6.0M (545,455 @ $11.00) |
| Dec 11, 2018 | Avalon X SPV, L.P. | 10% Owner | Buy | $6.0M (545,455 @ $11.00) |
| Dec 11, 2018 | Tighe Reardon | Acting Chief Financial Officer | Buy | $6.0M (545,455 @ $11.00) |
| Dec 11, 2018 | Orbimed Advisors LLC | Director | Buy | $15.0M (1,363,636 @ $11.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.